Reply by Tapper, Elliot B. et al.
Prediction of Hepatic Encephalopathy: Why Disregard
Well-Known Risk Factors?
TO THE EDITOR:
We read with interest the paper by Tapper et al.,(1)
who performed a retrospective cohort study of all
patients with cirrhosis without baseline hepatic ence-
phalopathy (HE) by extracting information from the
Veterans Administration database. The authors used
two readily available laboratory tests and a brief inven-
tory of the medication list to develop a simple scoring
system to identify patients at risk for HE.
In our opinion, some criticisms should be applied
to this study. The authors included several parame-
ters in their analysis; however, they did not consider
some very well-known risk factors for HE develop-
ment—namely, previous HE episodes, minimal
HE,(2) and the presence of porto-systemic shunts
(spontaneous or iatrogenic)—likely because of the
lack of data in a database that was not designed to
meet the study’s specific goal. This probably explains
the low performance of the model in terms of sensi-
tivity and specificity. Moreover, albumin levels may
vary because of the need for plasma expansion, and
this unknown variable is difficult to control in retro-
spective studies. Finally, the statistical approach raises
some concerns, because the standard armamentarium
of Kaplan-Meier survival estimates and Cox regres-
sion was used to evaluate the proportion of patients
who developed HE and the associated risk factors
without acknowledging that HE incidence should be
considered as an event competing with other out-
comes (e.g., liver transplantation and death).(3)
Moreover, no validation of the model (either internal
or external) was provided, making its performance
more uncertain regarding the identification of
patients at risk for HE.
In future studies, the lack of data both on previous
HE and covert HE will be unjustified, as the first
parameter may be objectively definite(4) and the diag-
nostic difficulties for covert HE assessment can be
overcome using a simple diagnostic tool, such as the
recently described Animal Naming Test.(5)
Because HE is prognostically relevant, associated
with low quality of life and representing a significant
socioeconomic burden, the identification of patients
who are at risk for this condition is an important goal.
Models with a better performance are therefore critical
to avoid this challenging complication of liver disease,
and a specifically designed database and a correct sta-
tistical approach will be essential if this goal is to be
met.
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Reply
We thank Drs. Ridola and Riggio for their interest
in our study on the risk of hepatic encephalopathy
(HE) in a population-based cohort of American veter-
ans.(1) In their letter, Drs. Ridola and Riggio raised
several interesting points. First, they requested that we
apply competing-risk analysis to our data set. We have
redone the analyses using competing-risk regression
based on Fine and Gray’s proportional subhazards
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model (Table 1). The statistical significance of final
model selections is no different, and effect estimates
are largely unchanged.
We also agree with Ridola and Riggio that the pres-
ence of minimal HE is predictive of incident overt
HE.(2) However, minimal HE is not routinely eval-
uated in clinical practice. Further, studies of minimal
HE diagnostics, such as the animal naming test,(3) uni-
formly excluded patients with psychiatric disorders,
alcohol misuse in the previous 6 months, any psycho-
active medication, and heart, respiratory, or renal fail-
ure. These comorbidities characterize roughly half of
our cohort. The optimal cutoffs as well as their per-
formance in real-world patients require future study.
To effectively risk-stratify real-world patients in an
intention-to-screen fashion, future studies of multimo-
dal approaches, including our risk score and other
modalities such as the EncephalApp and the animal
naming test, are indicated.
Ridola and Riggio raised three additional issues that
deserve clarification. First, validation: we performed an
internal validation using a bootstrapping method.
Second, we excluded patients with a history of overt
HE at baseline. Our goal was to predict incident overt
HE and not recurrent HE as patients with a history of
overt HE are known to be at high risk of recurrent
HE. Third, albumin levels can vary and are subject to
confounding by malnutrition and ascites. We agree.
However, both malnutrition (associated with sarcope-
nia or zinc deficiency) and ascites (an indicator of
severe portal hypertension) are also expected to be
associated with the risk of HE.
Elliot B. Tapper, M.D.
David Ratz, M.A.
Anna S.-F. Lok, M.D.
Grace L. Su, M.D.
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Intention-to-Treat Survival Benefit in Liver Transplantation:
Comments on Lai et al.
TO THE EDITOR:
We read with interest the article of Lai et al.(1)
which introduced an intention-to-treat (ITT) survival
benefit of liver transplantation (LT) in patients with
hepatocellular cancer (HCC).
The researchers developed two models: a pre-LT
model (non-LT survival model) and a post-LT model
(ITT LT survival model). This split into two models is
not innovative as is stated, ignoring Merion et al.(2)
and Schaubel et al.(3)
The researchers underlined the importance of the
informative censorship in the pre-LT model.
TABLE 1. Similar Results Obtained With Original Cox






Baseline model Albumin 0.54 (0.49-0.60) 0.71 (0.64-0.78)
Bilirubin 1.07 (1.05-1.09) 1.05 (1.03-1.08)
Beta-blocker 1.27 (1.04-1.55) 1.26 (1.02-1.55)
Statin 0.75 (0.61-0.90) 0.72 (0.58-0.87)
Longitudinal
model
Albumin 0.42 (0.38-0.46) 0.59 (0.54-0.66)
Bilirubin 1.11 (1.09-1.13) 1.07 (1.04-1.11)
Beta-blocker 1.51 (1.28-1.77) 1.68 (1.39-2.02)
Statin 0.79 (0.65-0.96) 0.75 (0.61-0.91)
*Baseline models only include variables as assessed at study
enrollment, whereas longitudinal models update inputs as the
values change. In the new competing-risk regression, the signifi-
cance of the final parameters is unchanged and effect size esti-
mates, if different, have not changed in clinically meaningful
ways.
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